A global pivotal study in participants with KRAS G12C-mutant, locally advanced or metastatic non-small cell lung cancer comparing first- line treatment of LY3537982 and Pembrolizumab vs placebo and Pembrolizumab in those with PD-L1 expression .50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 expression

Description

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT06119581 Opens a new window